Johnson & Johnson (JNJ) vs. Eli Lilly (LLY)

Company Profile

Johnson & Johnson (JNJ) and Eli Lilly (LLY) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Historical Performance

Historical Performance at a Glance

Profitability

Both Johnson & Johnson (JNJ) at 26.26% and Eli Lilly (LLY) at 101.31% rank in the top quartile for Return on Equity (TTM) among industry peers, indicating strong returns on shareholders’ equity.

Both Johnson & Johnson (JNJ) at 21.83% and Eli Lilly (LLY) at 34.99% rank in the top quartile for Net Profit Margin (TTM) among industry peers, indicating both companies convert revenue into net income more strongly than typical competitors.

Both Johnson & Johnson (JNJ) at 25.88% and Eli Lilly (LLY) at 43.63% rank in the top quartile for Operating Profit Margin (TTM) among industry peers, indicating both companies convert revenue into operating income more strongly than typical competitors.

Profitability at a Glance

Financial Strength

Both Johnson & Johnson (JNJ) at 1.03 and Eli Lilly (LLY) at 1.50 run Current Ratio (MRQ) in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Johnson & Johnson (JNJ) at 0.68 carries Debt-to-Equity Ratio (MRQ) around its industry mid-range, while Eli Lilly (LLY) at 1.39 sits in the higher-leverage quartile.

Both Johnson & Johnson (JNJ) at 34.01 and Eli Lilly (LLY) at 20.36 rank in the top quartile for Interest Coverage Ratio (TTM) among industry peers, indicating ample headroom to cover interest payments from operating income or EBIT.

Financial Strength at a Glance

Growth

Revenue Growth

Revenue Growth at a Glance

EPS Growth

EPS Growth at a Glance

Dividend

Both Johnson & Johnson (JNJ) at 2.26% and Eli Lilly (LLY) at 0.57% report Dividend Yield (TTM) near their industry mid-ranges, so neither company stands out strongly from peers on cash yield relative to share price.

Both Johnson & Johnson (JNJ) at 59.52% and Eli Lilly (LLY) at 22.10% post Dividend Payout Ratio (TTM) outside their industries’ typical mid-range — either leaning toward more retention or more distribution than the industry median.

Dividend at a Glance

Valuation

Both Johnson & Johnson (JNJ) at 26.37 and Eli Lilly (LLY) at 38.63 post Price-to-Earnings Ratio (TTM) near the typical industry midpoint — neither company stands out strongly from peers on trailing earnings multiple.

Both Johnson & Johnson (JNJ) at 5.76 and Eli Lilly (LLY) at 13.51 post Price-to-Sales Ratio (TTM) near the typical industry midpoint — neither company stands out strongly from peers on trailing revenue multiple.

Johnson & Johnson (JNJ) at 7.19 hovers around the typical industry Price-to-Book Ratio (MRQ), while Eli Lilly (LLY) at 27.85 sits above its industry benchmark range — an elevated book-value multiple for LLY relative to peers.

Valuation at a Glance